Emerging Agents and Future Strategies in Relapsed/Refractory CLL

Video content above is prompted by the following:

• Briefly comment on the role of non-covalent BTKis in this setting and available supporting data (high level). BRUIN CLL-321 – Sharman JP, et al. ASH 2024. Abs 886
  

Relapsed/Refractory CLL with TP53 mutation or del(17p)

• Briefly review recent ESMO guideline updates for managing patients with R/R CLL and TP53 mutations or del(17p).
  • What is your preferred treatment approach in this setting?
  • What factors/data do you use to guide your treatment decision in this setting?
    

Other Treatment Strategies in the 3L in and Beyond

• Briefly comment on the role of CAR T therapy in managing R/R CLL and available supporting data.
  • TRANSCEND CLL-004 –Siddiqi T, et al. ASH 2024. Abs 4633 
  • In what scenarios do you see a role for this approach, and which patients would you consider for this treatment?

Module III: Looking Ahead: Future Perspective in CLL (15 min)

• Briefly share your perspective/insights on emerging novel agents in R/R CLL.
  • Combination approaches with venetoclax
    • Venetoclax + acalabrutinib
    • Venetoclax + pirtobrutinib
  • BTKi degraders:
    • BGB-16673 - Parrando, et al EHA S157. Abs S157 
    • NX-5948 - Shah NN, et al. ASH 2024. Abs 884
  •  Bispecific antibodies: 
    • Epcoritamab - Danilov A, et al. ASH 2024. Abs 883 
  • 2^nd gen BCL2 inhibitors: 
    • Sonrotoclax - Soumerai JD, et al. ASH 2024. Abs 1012
    • Lisaftoclax - Davids MS, et al. ASH 2024. Abs 4614